Please Wait
Applying Filters...
menu
    • menu
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Laboratorium Ofichem, offering a flexible, high-tech environment to produce broad range of APIs for Human & Vet pharmaceutical markets.

    Virtual Booth

    Contact Supplier

    Menu

    Stenoparib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Allarity Therapeutics Doses Second Patient in Stenoparib Phase 2
    Allarity Therapeutics Doses Second Patient in Stenoparib Phase 2

    27 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/27/3106506/0/en/Allarity-Therapeutics-Announces-Dosing-of-Second-Patient-in-New-Phase-2-Trial-of-Stenoparib-in-Advanced-Ovarian-Cancer.html

    GLOBENEWSWIRE
    27 Jun 2025
    Share Share
    Allarity Dose 1st Patient in Ph2 Stenoparib Ovarian Cancer Trial
    Allarity Dose 1st Patient in Ph2 Stenoparib Ovarian Cancer Trial

    05 Jun 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/diagnostic-center/allarity-announces-enrolment-of-first-patient-in-phase-2-clinical-trial-protocol-of-stenoparib-in-advanced-ovarian-cancer-17245

    INDPHARMAPOST
    05 Jun 2025
    Share Share
    Allarity Therapeutics Enrolls First Patient in Stenoparib Phase 2
    Allarity Therapeutics Enrolls First Patient in Stenoparib Phase 2

    02 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/02/3091778/0/en/Allarity-Therapeutics-Announces-First-Patient-Enrolled-in-New-Phase-2-Clinical-Trial-Protocol-of-Stenoparib-in-Advanced-Ovarian-Cancer.html

    GLOBENEWSWIRE
    02 Jun 2025
    Share Share
    Allarity Therapeutics Q1 2025 Update: Stenoparib Benefit
    Allarity Therapeutics Q1 2025 Update: Stenoparib Benefit

    09 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/09/3078515/0/en/Allarity-Therapeutics-Provides-First-Quarter-2025-Update-Highlighting-Continued-Stenoparib-Benefit-and-Upcoming-Trial-Enrollment.html

    GLOBENEWSWIRE
    09 May 2025
    Share Share
    Allarity's Ph2 Stenoparib Lung Cancer Trial Fully Funded By VA
    Allarity's Ph2 Stenoparib Lung Cancer Trial Fully Funded By VA

    06 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/06/3038114/0/en/Allarity-Therapeutics-Announces-Phase-2-Trial-of-Stenoparib-in-Combination-with-Temozolomide-for-Recurrent-Small-Cell-Lung-Cancer-Fully-Funded-by-the-US-Veterans-Administration.html

    GLOBENEWSWIRE
    06 Mar 2025
    Share Share
    Allarity to Start Phase 2 for Stenoparib in Ovarian Cancer
    Allarity to Start Phase 2 for Stenoparib in Ovarian Cancer

    24 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/24/3031065/0/en/Allarity-Therapeutics-to-Begin-Enrollment-for-New-Phase-2-Protocol-to-Advance-Stenoparib-Toward-FDA-Approval-in-Advanced-Ovarian-Cancer-Patients.html

    GLOBENEWSWIRE
    24 Feb 2025
    Share Share